Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - mokro makularna degeneracija - ophthalmologicals - beovu prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd).

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - mišićna atrofija, kralješnica - ostali lijekovi za poremećaje mišićno-koštanog sustava - zolgensma indiciran za liječenje bolesnika s 5v spinalne mišićne atrofije (agr) sa bi-аллельные mutacije u genu smn1 i kliničku dijagnozu agr tip 1, orpatients sa 5v agr s bi-аллельные mutacije u genu smn1 i do 3-x kopija gena smn2.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - sredstva za modifikaciju lipida - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

uniqure biopharma b.v.  - alipogen tiparvovec - hyperlipoproteinemia type i - sredstva za modifikaciju lipida - glybera je indicirana za odrasle pacijente s dijagnozom obiteljskog deficita lipaze lipoproteina (lpld) i koji pate od teških ili višestrukih napada pankreatitisa unatoč ograničenjima prehrambenih masnoća. dijagnoza lpld mora biti potvrđena genetskim testiranjem. oznaka je ograničena na pacijente s detektabilnim razinama lpl proteina.

Europska Unija - hrvatski - EMA (European Medicines Agency)

omrix biopharmaceuticals n. v. - ljudskog fibrinogena, ljudskog trombina - hemostaza - lokalni кровоостанавливающие - potporno liječenje u kirurgiji odraslih gdje su standardne kirurške tehnike nedovoljne (vidi odjeljak 5. 1):- za poboljšanje hemostaze.